العنوان البديل: Cardiovascular safety of sitagliptin added to metformin in real world patients with type 2 diabetes. (English)

المؤلفون: 刘佐相, 陈晓薇, 赵厚宇, 詹思延, 孙凤

المصدر: Journal of Health Sciences of Peking University / Beijing Daxue Xuebao (Yixue Ban); Jun2024, Vol. 56 Issue 3, p424-430, 7p

العنوان البديل: Research Status and Trends of Cohort Studies on Efficacy Evaluation of Traditional Chinese Medicine： A Bibliometrix-based Visual Analysis on Literature from 2017 to 2022. (English)

المؤلفون: 龙子临, 赵厚宇, 廖星, 刘俊昌, 孙奇, 王程, 费宇彤, 宋海波, 詹思延, 孙凤

المصدر: Journal of Traditional Chinese Medicine (1001-1668); 4/2/2024, Vol. 65 Issue 7, p737-744, 8p

المؤلفون: 孙凤, 詹思延

الوصف: "网络Meta分析研究进展系列"合计20篇文章,从2020年6月至2022年1月,陆续发表在《中国循证心血管医学杂志》,作者为北京大学公共卫生学院孙凤、詹思延团队。

العلاقة: https://zenodo.org/record/7129116Test; https://doi.org/10.5281/zenodo.7129116Test; oai:zenodo.org:7129116

الإتاحة: https://doi.org/10.5281/zenodo.7129116Test
https://doi.org/10.5281/zenodo.7129115Test
https://zenodo.org/record/7129116Test

العنوان البديل: Association between metformin and the risk of Parkinson′s disease in patients with type 2 diabetes: a retrospective cohort study based on data from Yinzhou District, Ningbo City. (English)

المؤلفون: 柴三葆, 赵厚宇, 孙烨祥, 沈鹏, 林鸿波, 詹思延, 孙凤

المصدر: Chinese Journal of Diabetes Mellitus; Oct2023, Vol. 15 Issue 10, p963-971, 9p

الملخص (بالإنجليزية): Objective To explore the association between metformin use and the risk of Parkinson′s disease (PD) in patients with type 2 diabetes mellitus (T2DM) in Yinzhou District, Ningbo City. Methods　This was a retrospective cohort study and T2DM patients were recruited from the Yinzhou Regional Health Care Database as research subjects. This study adopted an active drug control and new drug user design, with sulfonylurea drugs as the control, in which a cohort of new users of metformin or sulfonylureas after January 1, 2009 was assembled. Inverse probability of treatment weighting (IPTW) was used to control for the baseline confounding factors, and the Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of the association between Met use and incidence of PD. Results　A total of 79 111 patients with T2DM were included. The cohort included 41 116 new users of metformin and 37 995 new users of sulfonylureas. During the follow-up period, there were 799 incident cases of PD occurred, 471 were in the sulfonylurea group and 328 were in the metformin group. The incidence rates were 186.7 per 100 000 person-years (471/252 326)and 147.7 per 100 000 person-years (328/222 011), respectively. Compared with sulfonylureas, the crude analysis without adjusting any confounding showed that there was a significant negative association between the use of metformin and the incidence of PD, with an HR of 0.80 (95%CI 0.70-0.93). After adjusting for potential confounders with IPTW, metformin was not significantly associated with the risk of PD (HR=0.88, 95%CI 0.76-1.01). The results of the subgroup and sensitivity analyses were generally consistent with those of the primary analysis. Conclusion　There is no significant association between the use of metformin and the risk of PD in T2DM patients in Yinzhou District, Ningbo City. [ABSTRACT FROM AUTHOR]

Abstract (Chinese): 目的　探讨宁波市鄞州区2型糖尿病（T2DM）患者使用二甲双胍（Met）与帕金森病（PD） 发病风险的关联。方法　回顾性队列研究, 选取宁波市鄞州区医疗数据平台中的T2DM患者作为研 究对象。采用活性药物对照、新用药者设计, 以磺脲类药物（SU）作为对照, 构建2009年1月1日后新 使用Met或SU的T2DM患者队列。使用逆治疗概率加权（IPTW）来控制基线的混杂因素, 并使用Cox 回归模型估计Met与PD发病风险之间关联的HR值及其95%CI。结果　共纳入79 111例T2DM患者。 其中, Met新使用者41 116例, SU新使用者37 995例。随访期间有799例患者发生PD, 其中471例为 SU 使用者, 328 例为Met 使用者, 发病率分别为186.7/10 万人年（471/252 326）和147.7/10 万人年 （328/222 011）。与SU相比, 不调整混杂的粗分析结果显示, Met与PD的发病率之间存在显著的负相 关（HR=0.80, 95%CI 0.70~0.93）。使用IPTW校正潜在混杂因素后, Met与PD的发病风险关联无统计 学意义（HR=0.88, 95%CI 0.76~1.01）。不同亚组分析和敏感性分析的结果与主分析的结果基本一致。 结论　宁波市鄞州区T2DM患者使用Met与PD的发病风险无显著相关性。. [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Diabetes Mellitus is the property of Chinese Journal of Diabetes Mellitus and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: 孙凤, 詹思延

الوصف: "偏倚风险评估系列"合计9篇文章,从2017年7月至2018年12月,陆续发表在《中华流行病学杂志》,作者为北京大学公共卫生学院孙凤、詹思延团队。

العلاقة: https://zenodo.org/record/7129032Test; https://doi.org/10.5281/zenodo.7129032Test; oai:zenodo.org:7129032

الإتاحة: https://doi.org/10.5281/zenodo.7129032Test
https://doi.org/10.5281/zenodo.7129031Test
https://zenodo.org/record/7129032Test

العنوان البديل: Clinical research progress and implications of therapeutic vaccines for cervical cancer and precancerous lesions: a qualitative systematic review. (English)

المؤلفون: 蔡珊, 缪珂, 谭小玉, 程思, 李丹彤, 曾雪扬, 杨羽, 孟若谷, 刘志科, 李燕, 李克莉, 孙凤, 詹思延

المصدر: Chinese Journal of Oncology; Jul2022, Vol. 44 Issue 7, p743-760, 18p

الملخص (بالإنجليزية): Objective To systematically summarize and analyze the clinical research progress of therapeutic vaccines for cervical cancer or precancerous lesions. Methods English databases (PubMed, Embase, Web of Science, Cochrane library, Proquest, and ClinicalTrails.gov) and Chinese databases (SinoMed, CNKI, WanFang, and VIP Database) were systematically searched to collect literature on therapeutic vaccines for cervical cancer or precancerous lesions from inception to February 18, 2021. After screening, we evaluated the risk of bias of included studies, and combed the basic information of the literature, research designs, information of vaccines, study patients, outcome indicators and so on, qualitatively summarized the clinical research progress. Results A total of 71 studies were included in this systematic review, including 14 random controlled trials, 15 quasi-random controlled trials, 4 cohort studies, 1 case-control study, 34 case series studies and 3 case reports. The study patients included women aged 15~79 with cervical cancer or precancerous lesions in 18 countries from 1989 to 2021. On the one hand, there were 40 studies on therapeutic vaccines for cervical precancerous lesions (22 867 participants), involving 21 kinds of vaccines in 6 categories. Results showed 3 marketed vaccines (Cervarix, Gardasil, Gardasil 9) as adjuvant immunotherapies were significant effective in preventing the recurrence of precancerous lesions compared with the conization only. In addition, MVA E2 vaccine had been in phase Ⅲ clinical trials as a specific therapeutic vaccine, with relative literature showing it could eliminate most high-grade precancerous lesions. Therapeutic vaccines for precancerous lesions all showed good safety. On the other hand, there were 31 studies on therapeutic vaccines for cervical cancer (781 participants), involving 19 kinds of vaccines in 7categories, with none had been marketed. 25 studies were with no control group, showing the vaccines could effectively eliminate solid tumors, prevent recurrence, and prolong the median survival time. However, the vaccines effectiveness couldn′t be statistically calculated due to the lack of a control group. As for the safety of therapeutic vaccines for cervical cancer, 9 studies showed that patients experienced serious adverse events after treatments, where 7 studies reported that serious adverse events occurred in patients couldn′t be ruled out as the results of therapeutic vaccines. Conclusions The literature review shows that the literature evidence for the therapeutic vaccines for cervical precancerous lesions is relatively mature compared with the therapeutic vaccines for cervical cancer. The four kinds of vaccines on the market are all therapeutic vaccines for precancerous lesions, but they are generally used as vaginal infection treatments or adjuvant immunotherapies for cervical precancerous lesions, not used for the specific treatments of cervical precancerous lesions. Other specific therapeutic vaccines are in the early stage of clinical trials, mainly phase Ⅰ/Ⅱ clinical trials with small sample size. The effectiveness and safety data are limited, and further research is still needed. [ABSTRACT FROM AUTHOR]

Abstract (Chinese): 目的 系统总结并分析宫颈癌及癌前病变治疗性疫苗的临床研究进展。 方法 系统检索PubMed、Embase、Web of Science、Cochrane Library、Proquest、ClinicalTrails.gov、SinoMed、中国知网、维普网、万方数据知识服务平台，检索日期为建库至2021年2月18日。对纳入的合格研究进行质量评价，并从文献基本信息、研究设计、疫苗信息、研究对象、结局指标等多方面归纳梳理，定性总结临床研究进展。 结果 共纳入71篇文献，其中随机对照试验14篇，类实验研究15篇，队列研究4篇，病例对照研究1篇，病例系列研究34篇，病例报告3篇。研究对象包括1989—2021年18个国家15~79岁患子宫颈癌或癌前病变的女性。癌前病变治疗性疫苗类文献40篇(n＝22 867))，涉及疫苗6类21种。研究结果显示，与对照组比较，3种已上市的疫苗[希瑞适(Cervarix)、四价疫苗(Gardasil)、九价疫苗(Gardasil 9)]作为辅助免疫治疗在预防癌前病变复发方面具有显著疗效。特异性治疗性疫苗改良牛痘安卡拉E2重组疫苗相关研究已到临床Ⅲ期，改良牛痘安卡拉E2重组疫苗能完全消除大部分高级别癌前病变。癌前病变治疗性疫苗均显示出良好的安全性。子宫颈癌治疗性疫苗类文献31篇(n＝781)，涉及疫苗7类19种，均未上市。25篇文献研究为无对照研究，结果显示，疫苗在实体瘤疗效评估、预防宫颈癌复发、延长中位生存时间等方面有效，但由于研究缺少对照组，疫苗疗效无法进行统计学检验。9篇研究显示患者经治疗出现严重不良事件，7篇文献报道患者出现的严重不良事件不能排除是宫颈癌治疗性疫苗导致的结果。 结论 与宫颈癌治疗性疫苗比较，癌前病变治疗性疫苗的文献证据相对较成熟。已上市的4种疫苗均为宫颈癌癌前病变治疗性疫苗，但一般作为手术辅助免疫治疗或阴道感染治疗，不作特异性治疗使用。其他宫颈癌及癌前病变特异性治疗性疫苗均处于研究初期，以小样本量Ⅰ或Ⅱ期临床试验为主，有效性和安全性数据有限，仍有待进一步研究。 [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

العنوان البديل: Epidemiological study on the incidence of inflammatory bowel disease in Yinzhou District, Ningbo City from 2011 to 2020. (English)

المؤلفون: 贺冰洁, 刘志科, 沈鹏, 孙烨祥, 陈彬, 詹思延, 林鸿波

المصدر: Journal of Health Sciences of Peking University / Beijing Daxue Xuebao (Yixue Ban); 2022, Vol. 54 Issue 3, p511-519, 9p

العنوان البديل: Utilizing social media data in post-market safety surveillance. (English)

المؤلفون: 杨羽, 王胜锋, 詹思延

المصدر: Journal of Health Sciences of Peking University / Beijing Daxue Xuebao (Yixue Ban); Jun2021, Vol. 53 Issue 3, p623-627, 5p

العنوان البديل: Epidemiological study of infantile epilepsy incidence density among infants under 36 months of age in Ningbo City from 2015 to 2019. (English)

المؤلفون: 姚晓莹, 刘志科, 李宁, 马瑞, 赵薛飞, 张良, 许国章, 詹思延, 方挺

المصدر: Journal of Health Sciences of Peking University / Beijing Daxue Xuebao (Yixue Ban); Jun2021, Vol. 53 Issue 3, p485-490, 6p

العنوان البديل: Epidemiological and etiological characteristics of hand,foot and mouth disease among children aged 5 years and younger in Ningbo （2016 to 2019）. (English)

المؤلفون: 刘立立, 刘志科, 张良, 李宁, 方挺, 张栋梁, 许国章, 詹思延

المصدر: Journal of Health Sciences of Peking University / Beijing Daxue Xuebao (Yixue Ban); Jun2021, Vol. 53 Issue 3, p491-497, 7p